The Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for gene therapy development.
The demand for gene therapies – and the materials required to manufacture gene therapies – is growing at a rapid rate.
There are currently 3,633 advanced therapies in the pre-clinical to pre-registration pipelines. Of these, 55%, or 1,998, are gene therapies [1]. Comparing the number of gene therapies in the pipeline at the start of 2021 to the beginning of 2022, there has been a 16% increase, with this number continuing to rise [1].
In total, there are currently 19 gene therapies including genetically modified cell therapies approved for commercial treatment of patients. With increasing demand, however, comes increased pressure from manufacturing-specific challenges. With this eBook, produced in partnership with WuXi Advanced Therapies, we aim to provide possible solutions to some of the more pressing obstacles in this space, so that ultimately, more patients can benefit from access to these treatments.
In this eBook, you will find:
- The Clinical Landscape of Gene Therapies in 2022
- Gene Therapies: The Road to Regulatory Approval
- 5 Things to Consider When Sourcing Plasmids
- What to Look for in a Transient AAV Platform
- A Novel Technology for AAV Manufacture: TESSA™ in the Spotlight
As always, we hope you enjoy this eBook.
Fill in the form below to download the full eBook.
